News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Covalon Technologies Ltd. to Unveil its SilverCoatâ„¢ Antimicrobial Silicone Foley Catheter at the 2012 American Urological Association Annual Meeting in Atlanta



5/21/2012 10:32:37 AM

MISSISSAUGA, ON, May 18, 2012 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced it will be showcasing its advanced medical coating capabilities, including its SilverCoatTM Antimicrobial Silicone Foley Catheter as well as its recently FDA cleared IV Clear antimicrobial silicone adhesive film dressing from May 19th to May 23rd at the American Urological Association 2012 Annual Meeting ("AUA") in Atlanta, Georgia.

"We are looking forward to presenting our SilverCoat Antimicrobial Silicone Foley Catheter, with its lubricious and antimicrobial coating at the AUA," said Brian Pedlar, Covalon's Chief Executive Officer. "We have demonstrated that our antimicrobial coating outperforms market-leading silver coated Foley catheters in killing the bacteria most commonly associated with urinary tract infections. The AUA provides Covalon with a great opportunity to showcase our urological care products to an international audience, including close to three hundred leading manufacturers, wholesalers and distributors."

Urinary tract infections have been identified by the United States Center for Disease Control as the most common type of healthcare associated infection, of which 75% are associated with a urinary catheter, often referred to as CAUTIs. The Centers for MediCare and Medicaid Services are no longer reimbursing medical institutions for the treatment of CAUTIs.

Now in its 107th year, the AUA Annual Meeting is the largest gathering of urologists in the world, providing unparalleled access to groundbreaking research, new guidelines and the latest advances in urologic medicine.

Covalon will also be showcasing its advanced wound and antimicrobial silicone adhesive technology. These exciting new products will be available for license or distribution, following regulatory clearance to our growing domestic and international distribution channels and to medical product companies who are looking to license breakthrough new products.

To learn more about Covalon's products and services, please visit us at booth 3756 in the Georgia World Congress Center from May 19th to 23rd or contact Brian Pedlar, CEO, Covalon Technologies Ltd. at bpedlar@covalon.com.

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com Follow us on Twitter @covalon

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

SOURCE Covalon Technologies Ltd.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES